A real-world disproportionality analysis of adverse events associated with lenvatinib in thyroid cancer patients based on the FAERS database
This pharmacovigilance study of over 2,400 FAERS reports reveals that lenvatinib treatment in thyroid cancer patients is associated with significant vascular, renal, and cardiac risks, identifies seven novel adverse events not listed on the FDA label, and uncovers a biphasic time-to-onset pattern that supports stratified clinical monitoring.